Stocks should rally if the U.S. and China agree to new negotiations and a ceasefire in the trade war, but the economic impact of tariffs will continue.Market Insiderread more
Democrats want Mueller's testimony on his probe into Russian interference in the 2016 election and Trump's efforts to influence it.Politicsread more
The trade war between Beijing and Washington appears to have depressed Chinese property purchases in the United States. China's own actions may also be playing a role.Real Estateread more
More than 300 companies are talking to government officials in Washington about how detrimental the trade war is.Marketsread more
Powell stresses the central bank's independence in a speech that comes amid continuous pressure from the White House to cut interest rates.The Fedread more
The Senate is expected to pass its own version of the border aid legislation, while the Trump administration has threatened to veto both bills.Politicsread more
Markets in Asia fell on Wednesday morning after U.S. Federal Reserve Chairman Jerome Powell tempered expectations for a potential interest rate cut.Asia Marketsread more
In a text message, Grisham confirmed to CNBC that she will still be working for the first lady even as she takes on her new roles.Politicsread more
Acting Customs and Border Protection Commissioner John Sanders is resigning amid the furor over the Trump administration's treatment of migrant children.Politicsread more
NBC is taking the office back from Netflix as it seeks to bolster its own streaming service launching in 2020.Technologyread more
Wayfair employees plan to walk out tomorrow, after no action was taken in response to their opposition to the company supplying border detention camps with beds for children.Retailread more
Jim Cramer always abides by one simple rule. When there are accounting irregularities, you do not ask questions, you do not make excuses, you do not wait for clarity — you just sell.
A dark cloud has hung over Valeant ever since speculation began that it may use unorthodox methods to sell drugs. Cramer traced the initial charge of accounting irregularities to Andrew Left, of Citron Research.
"While unorthodox and inflammatory, Left has done some pretty good work, and I thought his allegations seemed well documented," Cramer said, "even as it seemed a little rash to call Valeant the pharmaceutical Enron."
At the time Left's statement was published, Valeant traded in the $120s and he gave it a $50 price target. Cramer had heard a lot of talk about price gouging at Valeant, but a lot of companies were raising drug prices at the time. So, he assumed Valeant was just more aggressive.
Read more from Mad Money with Jim Cramer
As soon as Cramer read Citron's report, he recognized that any potential upside simply was not worth it.
"You never want to get behind some stock when the accounting is being challenged, unless you have total comfort that the short seller is wrong," Cramer said.
The most promising bullish thesis on Valeant that Cramer found indicated that even if Philidor was being used to move inventory in a shady way, it would not hurt earnings that bad. And if Valeant slowed down price increases, it would still have amazing cash flow.
But Cramer stood by his rule firmly. He had not yet heard anything that the accounting was cleared, and when the stock plummeted he was glad his rule did not fail him.
Even as Walgreen's announced a deal with Valeant for discounted drugs, Cramer did not budge.
"Sorry, as much as we all may like and respect Walgreens … the fact is, they are not the U.S. government, and it is the government we need to be worried about here," Cramer said.
The second accounting bombshell dropped on Feb. 22 when the company said it had mistakenly recognized too much profit in 2014 and needed to have some of that shifted to 2015. Cramer knew to stay far away, as the SEC hates restatements and almost always opens an investigation into them.
Valeant now trades at roughly half of where it was when the first potential accounting irregularity surfaced.
Cramer has often been criticized for his rule, especially those that kept investors out of companies that were legitimate but tarred unfairly with accounting charges.
"It is true. I have been too cautious at times and have missed opportunities," Cramer said.
However, the pain in Valeant should be a constant reminder of how right his rule is. This stock has been a nightmare that simply could have been avoided by following one straightforward principle.